UPDATED 3:08 P.M.
(Reuters) – A panel of outside advisers to the U.S. Centers for Disease Control and Prevention on Thursday voted to recommend Americans choose to receive one of the other two authorized COVID-19 vaccines over Johnson & Johnson’s shot, due to rare but sometimes fatal cases of blood clotting.
The CDC’s Advisory Committee on Immunization voted unanimously to make the recommendation. The regulator still needs to sign off on the guidance.
Cases of thrombosis with thrombocytopenia syndrome (TTS), which involves blood clots accompanied by a low level of platelets, have previously been reported in recipients of the J&J vaccine. The highest reporting rates are in women under 50.
The CDC said that the rate of such incidents is higher than previously estimated, both in women and men.
At least nine people have died following the blood clotting incidents in the United States, the CDC has said.
Members of the panel also said J&J’s vaccine is less effective in preventing COVID-19 than the other two authorized vaccines.
In a presentation to the committee, a leading J&J vaccine scientist said the vaccine generates a strong and long-lasting immune response with just a single shot.
“In the setting where many people do not return for a second dose or a booster, the durability of the single shot Johnson & Johnson vaccine as a primary regimen could make a crucial difference in saving lives in the U.S. and around the globe,” J&J’s Dr. Penny Heaton said in the presentation.
J&J’s vaccine uses a technology based on a modified version of an adenovirus to spur immunity in recipients, while the other two authorized vaccines use messenger RNA technology.
J&J’s one-dose vaccine received emergency use authorization in March. In April, U.S. regulators paused administering the vaccine for 10 days in order to investigate the blood clotting.
A CDC scientist said on Thursday that the rate of deaths from TTS did not decrease after the pause in April.
Fewer Americans have received the J&J shot than the other two vaccines by a significant margin. Out of more than 200 million fully vaccinated people in the United States, around 16 million received J&J’s vaccine, according to CDC data.
(Reporting by Michael Erman in New Jersey, additional reporting by Manas Mishra in Bengaluru; Editing by Anil D’Silva and Howard Goller)
———–
(Reuters) -A panel of outside advisers to the U.S. Centers for Disease Control and Prevention was considering on Thursday whether to recommend that Americans choose to receive one of the two authorized messenger RNA (mRNA) COVID-19 vaccines over Johnson & Johnson’s shot, due to rare but sometimes fatal cases of blood clotting.
J&J’s vaccine uses a technology based on a modified version of an adenovirus to spur immunity in recipients, while the Moderna and Pfizer/BioNTech vaccines use mRNA technology.
The CDC’s Advisory Committee on Immunization practices was expected to vote on the issue on Thursday, after a subcommittee said it supported making the “preferential recommendation.”
Cases of thrombosis with thrombocytopenia syndrome, which involves blood clots accompanied by a low level of platelets, have previously been reported in recipients of the J&J vaccine.
The CDC said that the rate of such incidents is higher than previously estimated, both in women and men.
At least nine people have died following the blood clotting incidents in the United States, the CDC has said.
(Reporting by Michael Erman in New Jersey, additional reporting by Manas Mishra in Bengaluru; Editing by Anil D’Silva and Howard Goller)
Comments